Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

4.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 Next >
AbCellera Announces Changes to Its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q3 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Virtual Presentations at Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
From AbCellera Biologics Inc.
Via Business Wire
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
From AbCellera Biologics Inc.
Via Business Wire
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
From AbCellera Biologics Inc.
Via Business Wire
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
From AbCellera
Via Business Wire
AbCellera Reports Q2 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
From AbCellera Biologics Inc.
Via Business Wire
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
From Tachyon Therapeutics, Inc.
Via Business Wire
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Appoints Neil Berkley as Chief Business Officer
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
From AbCellera Biologics Inc.
Via Business Wire
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q1 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
From AbCellera Biologics Inc.
Via Business Wire
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
From AbCellera
Via Business Wire
AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021
From AbCellera
Via Business Wire
AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.